Bimekizumab for Hidradenitis Suppurativa
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications, but it mentions that participants should not receive prohibited treatments close to the Baseline Visit. It's best to discuss your current medications with the trial team to see if any adjustments are needed.
What data supports the effectiveness of the drug Bimekizumab for treating Hidradenitis Suppurativa?
Research shows that Bimekizumab, along with other similar drugs, leads to better outcomes than a placebo for treating Hidradenitis Suppurativa, without increasing the risk of side effects. It ranks second in effectiveness, just after Adalimumab, in achieving significant clinical response and improving quality of life within 12-16 weeks.12345
Is Bimekizumab safe for humans?
How does the drug Bimekizumab differ from other treatments for hidradenitis suppurativa?
What is the purpose of this trial?
The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
Research Team
UCB Cares
Principal Investigator
001 844 599 2273
Eligibility Criteria
This trial is for children and adolescents aged 12 to less than 18 with moderate to severe Hidradenitis Suppurativa (HS). They must have been diagnosed at least 6 months prior, have ≥5 inflammatory lesions in at least two areas, one being Hurley Stage II or III. Participants need a history of inadequate response to antibiotics for HS and weigh over 30kg.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a weight-dependent dose of bimekizumab subcutaneously
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Bimekizumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
UCB Biopharma SRL
Lead Sponsor
Jean-Christophe Tellier
UCB Biopharma SRL
Chief Executive Officer since 2015
MD from University of Reims Champagne-Ardenne, Rheumatology specialization from University of Paris V, Executive business programs at Harvard and INSEAD
Dr. Iris Loew-Friedrich
UCB Biopharma SRL
Chief Medical Officer since 2014
MD from University of Leuven, PhD in Medical Sciences from University of Leuven